The Utah Electrode Array is the most-implanted, most-studied intracortical BCI electrode in history.
Blackrock Neurotech
venture active confidence: Medium status: Draft updated 2026-07-14
Summary
Salt Lake City-based Blackrock Neurotech commercialized the Utah Electrode Array and is developing brain-computer systems for paralysis and locked-in syndrome. Restoring communication and movement from neural signals would reset a global medical frontier; decades of human research make that more than a speculative S-scale bet.
Impact
Blackrock's MoveAgain system — which translates motor-cortex signals into device commands for patients with paralysis, ALS, or locked-in syndrome — has FDA Breakthrough Device designation. The current generation of Utah Arrays gathers neural signals across up to 96–100 electrode channels per device. The company's next-generation device, Neuralace, is described in public materials as a flexible chip with more than 10,000 channels and the potential to enable a fidelity of brain-machine communication that doesn't yet exist.
The impact case has two paths. The first is direct clinical deployment: patients regaining functional independence. The second is substrate impact: hundreds of academic labs globally use the Utah Array as a recording standard, which makes Blackrock a critical infrastructure layer for the entire BCI research field.
What They Are Building
The company's product line spans implantable arrays, cabling and headstages, recording and stimulation systems, and the data and software that translate cortical signals into intent. The most consequential engineering problem they are working on is one that has been unsolved for decades: chronic stability. Implanted electrodes degrade as scar tissue forms; signal quality drops over months. The Neuralace flexible-mesh design is the company's bet on conforming to brain tissue rather than puncturing it.
For talent, the available evidence suggests Blackrock is a place where neuroscientists, electrical engineers, materials scientists, and signal-processing engineers can ship work that reaches human patients within their careers, not their successors'.
What They Need Now
Hiring emphasis runs to electrode R&D and manufacturing (engineers, technical project managers, technicians), BCI software leadership, IT and cybersecurity, and quality — plus intermittent BCI internships in data science and related teams. Neural engineers, materials scientists for biocompatible electrode interfaces, signal-processing and machine-learning engineers, regulatory engineers experienced with implantable Class III devices, and clinical operations leaders remain the broader fit.
The team also benefits from people who can work inside the unusual governance arrangement that comes with a strategic crypto-treasury majority owner — see the caveat below.
Who Could Help
Useful helpers include implantable-device regulatory counsel, FDA Breakthrough Device program specialists, clinical trial managers with neuro-implant experience, IP attorneys who understand the long-tail neural-interface patent landscape, and corporate-governance and finance advisors comfortable with non-traditional majority owners. The Utah neuroengineering and SCI Institute communities are particularly close-by intellectual peers.
Utah Context
Blackrock is part of a small but globally outsized Utah neuroengineering cluster: the University of Utah's neural engineering group, SCI Institute, Ripple Neuro, and Iris Biomedical. The Wasatch Front gives founders and engineers in this domain a peer set that is hard to assemble anywhere else.
Evidence
- Source: Blackrock Neurotech and the Utah Array · https://www.medicaldesignandoutsourcing.com/utah-array-brain-computer-interface-blackrock-neurotech/
- Utah Array BCI Platform — foundational University of Utah research behind the commercial electrode
- Source: Tether Strategic Stake in Blackrock Neurotech · https://tether.io/news/tether-takes-strategic-stake-in-leading-brain-computer-interface-company-blackrock-neurotech/
Open Questions
- The Tether majority stake reshapes the company's capital base and governance; observers should watch which Neuralace and BCI roadmap items get prioritized, and whether the unusual ownership structure helps or constrains FDA-track work.
- Competitors (Neuralink, Synchron, Precision Neuroscience) are pursuing related goals with very different funding and architecture; Blackrock's institutional advantage is its 30,000-patient-day track record, but the field is intensifying.